Brain Tumor Immunotherapy

[1]  R. Coleman,et al.  Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Coleman,et al.  Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. , 2000, International journal of radiation oncology, biology, physics.

[3]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[4]  R. Coleman,et al.  Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[6]  D. Wedekind,et al.  Tumor gene therapy made easy: allogeneic major histocompatibility complex in the C6 rat glioma model. , 1999, Human gene therapy.

[7]  J. Krauss,et al.  Systemic T cell adoptive immunotherapy of malignant gliomas. , 1998, Journal of neurosurgery.

[8]  R. Coleman,et al.  Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Foon,et al.  Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[11]  H. Kagamu,et al.  Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. , 1998, Journal of immunology.

[12]  P Black,et al.  Management of malignant glioma: role of surgery in relation to multimodality therapy. , 1998, Journal of neurovirology.

[13]  B. Fenton,et al.  Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. , 1998, Cancer research.

[14]  M. Ladanyi,et al.  Novel Tumor-Associated Surface Antigen: Broad Distribution among Neuroectodermal, Mesenchymal and Epithelial Tumors, with Restricted Expression among Normal Tissues † 785 , 1998, Pediatric Research.

[15]  K. Foon,et al.  Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2. , 1998, Journal of immunotherapy.

[16]  S. A. Azizi,et al.  Principles of treatment of malignant gliomas in adults: an overview. , 1998, Journal of neurovirology.

[17]  G. Giuliani,et al.  Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas , 1997, Cancer.

[18]  K. Foon,et al.  Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  J. Stears,et al.  Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2 , 1997, Cancer Immunology, Immunotherapy.

[20]  G. Plautz,et al.  Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. , 1997, Cellular immunology.

[21]  B. Kleinschmidt-DeMasters,et al.  Purified herpes simplex thymidine kinase Retrovector particles. I. In vitro characterization, in situ transduction efficiency, and histopathological analyses of gene therapy-treated brain tumors. , 1997, Cancer gene therapy.

[22]  V. Sondak,et al.  Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J Hildebrand,et al.  Management of malignant brain tumors. , 1997, European neurology.

[24]  G. Plautz,et al.  Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells. , 1996, Cancer research.

[25]  H. Young,et al.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Krauss,et al.  Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. , 1996, Cancer research.

[27]  J. Reimann,et al.  MHC class I-restricted CTL responses to exogenous antigens. , 1996, Immunity.

[28]  G. Plautz,et al.  Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors. , 1996, Cellular immunology.

[29]  F. Oesch,et al.  Granulocyte‐macrophage‐colony‐stimulating factor enhances immune responses to melanoma‐associated peptides in vivo , 1996, International journal of cancer.

[30]  R. Coleman,et al.  Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  L. Picker,et al.  Lymphocyte Homing and Homeostasis , 1996, Science.

[32]  D. Mercola,et al.  Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[33]  K. Rock.  A new foreign policy: MHC class I molecules monitor the outside world. , 1996, Immunology today.

[34]  E. Thorsby,et al.  Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study , 1996, International journal of cancer.

[35]  J. Krauss,et al.  Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. , 1996, Cancer gene therapy.

[36]  J. Gralow,et al.  Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. , 1996, Blood.

[37]  H. Hochster,et al.  Improved long term survival after intracavitary interleukin‐2 and lymphokine‐activated killer cells for adults with recurrent malignant glioma , 1995, Cancer.

[38]  R. McLendon,et al.  Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. , 1995, Cancer research.

[39]  A. Chang,et al.  Unique characteristics associated with systemic adoptive immunotherapy of experimental intracerebral tumors. , 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[40]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.

[41]  M. Davis,et al.  Antigen-specific development of primary and memory T cells in vivo. , 1995, Science.

[42]  W. Paulus,et al.  Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. , 1995, The American journal of pathology.

[43]  K. Hopkins,et al.  A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[44]  M. Dailey,et al.  Regulation of adhesion molecule expression by CD8 T cells in vivo. II. Expression of L-selectin (CD62L) by memory cytolytic T cells responding to minor histocompatibility antigens. , 1994, Journal of immunology.

[45]  J. Kemshead,et al.  The potential of targeted radiotherapy in the treatment of central nervous system leukaemia. , 1994, Leukemia & lymphoma.

[46]  J. Vilček,et al.  Phase Ib Trial of Granulocyte‐Macrophage Colony‐Stimulating Factor Combined with Murine Monoclonal Antibody R24 in Patients with Metastatic Melanoma , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[47]  K. Okumura,et al.  Selective expression of interleukin-10 gene within glioblastoma multiforme , 1994, Brain Research.

[48]  A. Chang,et al.  Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[49]  C. Sturiale,et al.  Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors , 1994, Cancer.

[50]  A. Chang,et al.  Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. , 1994, Journal of immunology.

[51]  A. Lobuglio,et al.  Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. , 1993, Journal of immunology.

[52]  M. Oldstone,et al.  Trafficking of activated cytotoxic T lymphocytes into the central nervous system: Use of a transgenic model , 1993, Journal of Neuroimmunology.

[53]  J. Kemshead,et al.  Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry. , 1993, British Journal of Cancer.

[54]  D. Bigner,et al.  Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates , 1992, International journal of cancer.

[55]  H. Antoniades,et al.  Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. , 1992, Journal of neurosurgery.

[56]  H. Koprowski,et al.  Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. , 1992, International journal of radiation oncology, biology, physics.

[57]  H. Schreiber,et al.  Tumor antigens. , 1992, Annual review of immunology.

[58]  D. R. Madden,et al.  The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation , 1991, Nature.

[59]  A. Chang,et al.  Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. , 1991, Journal of immunology.

[60]  D. Bigner,et al.  RADIOLABELED MONOCLONAL ANTIBODIES , 1991 .

[61]  P. Marrack,et al.  The staphylococcal enterotoxins and their relatives. , 1990, Science.

[62]  M. Mitchell.  Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  N. Patronas,et al.  The effect of intravenous interleukin-2 on brain water content. , 1989, Journal of neurosurgery.

[64]  G. Butti,et al.  Prostaglandin and thromboxane synthesis by human intracranial tumors. , 1989, Cancer research.

[65]  E. Oldfield,et al.  Intratumoral LAK cell and interleukin-2 therapy of human gliomas. , 1989, Journal of neurosurgery.

[66]  R. Merchant,et al.  Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. , 1988, Neurosurgery.

[67]  N. Takai,et al.  Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. , 1988, Cancer research.

[68]  E. Oldfield,et al.  Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. , 1988, Journal of neurosurgery.

[69]  A. Chang,et al.  Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity. , 1988, Journal of immunology.

[70]  H. Weiner,et al.  T Cells in Multiple Sclerosis and Inflammatory Central Nervous System Diseases , 1987, Immunological reviews.

[71]  M. A. Saper,et al.  Structure of the human class I histocompatibility antigen, HLA-A2 , 1987, Nature.

[72]  S. Rosenberg,et al.  Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. , 1987, Journal of immunology.

[73]  S. Rosenberg,et al.  In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice. , 1987, Cancer research.

[74]  J. Taylor‐Papadimitriou,et al.  Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. , 1986, Cancer research.

[75]  S. Jacobs,et al.  Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report. , 1986, Journal of neurosurgery.

[76]  W. Griffin,et al.  Functional capacity of solid tissue transplants in the brain: evidence for immunological privilege , 1985, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[77]  Raine Cs.  Biology of disease. Analysis of autoimmune demyelination: its impact upon multiple sclerosis. , 1984 .

[78]  M. Colombo,et al.  In vitro detection of cell‐mediated immunity to individual tumor‐specific antigens of chemically induced BALB/c fibrosarcomas , 1983, International journal of cancer.

[79]  T. Roszman,et al.  Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. , 1980, Clinical and experimental immunology.

[80]  K. Hellström,et al.  Unique and common tumor‐specific transplantation antigens of chemically induced mouse sarcomas , 1978, International journal of cancer.

[81]  D. Bigner,et al.  Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. , 1977, Journal of neurosurgery.

[82]  W. Brooks,et al.  Immune responses in patients with gliomas. , 1974, Surgical neurology.

[83]  M. Netsky,et al.  DEPRESSED CELL-MEDIATED IMMUNITY IN PATIENTS WITH PRIMARY INTRACRANIAL TUMORS , 1972, The Journal of experimental medicine.

[84]  R. Prehn,et al.  Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.

[85]  P. Medawar.  Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. , 1948, British journal of experimental pathology.